Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent

Rhea-AI Summary

Immutep Limited (NASDAQ: IMMP) announced the grant of a new patent in China for its lead product candidate, eftilagimod alpha (efti). This patent, numbered ZL 201610221687, protects the use of efti combined with chemotherapy for cancer treatment, expiring on October 3, 2028. This addition to Immutep's patent portfolio follows similar grants in Europe, Japan, and the US. The patent is exclusively licensed to EOC Pharma, which will pay milestone fees and royalties as efti progresses in clinical development.

Positive

• Grant of a new patent in China enhances the company's intellectual property portfolio.
• The patent supports the development of efti in conjunction with chemotherapy for cancer treatment.
• Partnership with EOC Pharma includes milestone payment opportunities, enhancing revenue potential.

Negative

• None.

SYDNEY, AUSTRALIA, Nov. 02, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number ZL 201610221687) entitled “Use of recombinant LAG-3 or the derivatives thereof for eliciting a monocyte immune response” by the Chinese Patent Office. The patent forms part of a broad and growing portfolio of patent families for the Company’s lead product candidiate eftilagimod alpha (“efti” or “IMP321”) in key global markets including China.

This new Chinese patent follows the grant of the corresponding European, Japanese and United States patents announced previously. The claims of the new patent relate to methods of use of (a) Immutep’s efti which is a LAG-3 fusion protein (LAG-3Ig) and (b) a chemotherapy agent in combination for the manufacture of a preparation for the treatment of cancer. The patent provides protection in mainland China and the expiry date is 3 October 2028.

The new patent is owned by Immutep S.A.S. and exclusively licensed to Immutep’s partner in China, EOC Pharma (“EOC”).

Immutep CEO, Marc Voigt, noted: “We are making good progress building our global patent estate around our LAG-3 development pipeline, including lead candidate efti which has delivered promising clinical data in various settings. We will continue to make these important investments and are especially pleased to be working so closely with our Chinese partner, EOC Pharma, as they expand their clinical development of efti for the Chinese market.”

EOC Pharma CEO, Xiaoming Zou, said: “We are investing in the development of efti for the local market in China and are very pleased with the steps being taken by our partner, Immutep, to build a broad portfolio of patent families around this unique candidate. These are important and ongoing steps in the complex process of bringing innovative medicines to the market for patients.”

About efti in China
Efti is exclusively licensed by Immutep to EOC Pharma for the territory of Greater China (namely mainland China, Hong Kong S.A.R, Macao S.A.R. and Taiwan). Under its agreement with Immutep, EOC will make further milestone payments to the Company if efti achieves specific development milestones, as well as pay sales-based royalties. Immutep retains the rights to efti outside the territory of Greater China.

About EOC Pharma
EOC Pharma is an integrated biopharmaceutical company focusing on the discovery, research, development and commercialisation of innovative oncology products. With an insight-driven strategy and integrated business platform, EOC Pharma strives to build a portfolio of products with strategic synergies from independent R&D and licensing and enrich the product pipeline with first- and best -in-class oncology drugs to benefit the millions of patients who currently have limited access to high quality oncology treatments in China.

About Immutep
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Immutep’s current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com

FAQ

What is the significance of the new patent granted to Immutep for IMMP?

The new patent enhances Immutep's intellectual property portfolio and supports the development of its lead product, efti, in China.

What are the financial implications of the patent granted to Immutep?

The patent allows Immutep to receive milestone payments and sales-based royalties from EOC Pharma as efti achieves specific milestones.

When does the new patent for efti expire?

The new patent for efti expires on October 3, 2028.

Who holds the rights to the efti patent in China?

The patent is owned by Immutep S.A.S. and exclusively licensed to EOC Pharma for the Greater China territory.

How does the new patent affect Immutep's market strategy for IMMP?

The patent strengthens Immutep's position in the Chinese market, facilitating collaborations and clinical developments through its partnership with EOC Pharma.